Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
Tolperisone hydrochloride is a centrally-acting muscle relaxant used for relieving spasticities of neurological origin and muscle spasms associated with painful locomotor diseases. It is metabolized to the inactive metabolite mainly by CYP2D6 and, to a lesser extent, by CYP2C19 and CYP1A2. In our pr...
Saved in:
| Published in | Archives of pharmacal research Vol. 46; no. 2; pp. 111 - 116 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Seoul
Pharmaceutical Society of Korea
01.02.2023
대한약학회 |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Tolperisone hydrochloride is a centrally-acting muscle relaxant used for relieving spasticities of neurological origin and muscle spasms associated with painful locomotor diseases. It is metabolized to the inactive metabolite mainly by CYP2D6 and, to a lesser extent, by CYP2C19 and CYP1A2. In our previous study, the pharmacokinetics of tolperisone was significantly affected by the genetic polymorphism of
CYP2D6
, but the wide interindividual variation of tolperisone pharmacokinetics was not explained by genetic polymorphism of
CYP2D6
alone. Thus, we studied the effects of
CYP2C19
genetic polymorphism on tolperisone pharmacokinetics. Eighty-one subjects with different
CYP2C19
genotypes received a single oral dose of 150 mg tolperisone with 240 mL of water, and blood samples were collected up to 12 h after dosing. The plasma concentration of tolperisone was measured by a liquid chromatography-tandem mass spectrometry system. The CYP2C19PM group had significantly higher C
max
and lower CL/F values than the CYP2C19EM and CYP2C19IM groups. The AUC
inf
of the CYP2C19PM group was 2.86-fold and 3.00-fold higher than the CYP2C19EM and CYP2C19IM groups, respectively. In conclusion, the genetic polymorphism of
CYP2C19
significantly affected tolperisone pharmacokinetics. |
|---|---|
| AbstractList | Tolperisone hydrochloride is a centrally-acting muscle relaxant used for relieving spasticities of neurological origin and muscle spasms associated with painful locomotor diseases. It is metabolized to the inactive metabolite mainly by CYP2D6 and, to a lesser extent, by CYP2C19 and CYP1A2. In our previous study, the pharmacokinetics of tolperisone was significantly affected by the genetic polymorphism of CYP2D6, but the wide interindividual variation of tolperisone pharmacokinetics was not explained by genetic polymorphism of CYP2D6 alone. Thus, we studied the effects of CYP2C19 genetic polymorphism on tolperisone pharmacokinetics. Eighty-one subjects with different CYP2C19 genotypes received a single oral dose of 150 mg tolperisone with 240 mL of water, and blood samples were collected up to 12 h after dosing. The plasma concentration of tolperisone was measured by a liquid chromatography-tandem mass spectrometry system. The CYP2C19PM group had significantly higher Cmax and lower CL/F values than the CYP2C19EM and CYP2C19IM groups. The AUCinf of the CYP2C19PM group was 2.86-fold and 3.00-fold higher than the CYP2C19EM and CYP2C19IM groups, respectively. In conclusion, the genetic polymorphism of CYP2C19 significantly affected tolperisone pharmacokinetics. KCI Citation Count: 0 Tolperisone hydrochloride is a centrally-acting muscle relaxant used for relieving spasticities of neurological origin and muscle spasms associated with painful locomotor diseases. It is metabolized to the inactive metabolite mainly by CYP2D6 and, to a lesser extent, by CYP2C19 and CYP1A2. In our previous study, the pharmacokinetics of tolperisone was significantly affected by the genetic polymorphism of CYP2D6, but the wide interindividual variation of tolperisone pharmacokinetics was not explained by genetic polymorphism of CYP2D6 alone. Thus, we studied the effects of CYP2C19 genetic polymorphism on tolperisone pharmacokinetics. Eighty-one subjects with different CYP2C19 genotypes received a single oral dose of 150 mg tolperisone with 240 mL of water, and blood samples were collected up to 12 h after dosing. The plasma concentration of tolperisone was measured by a liquid chromatography-tandem mass spectrometry system. The CYP2C19PM group had significantly higher Cₘₐₓ and lower CL/F values than the CYP2C19EM and CYP2C19IM groups. The AUCᵢₙf of the CYP2C19PM group was 2.86-fold and 3.00-fold higher than the CYP2C19EM and CYP2C19IM groups, respectively. In conclusion, the genetic polymorphism of CYP2C19 significantly affected tolperisone pharmacokinetics. Tolperisone hydrochloride is a centrally-acting muscle relaxant used for relieving spasticities of neurological origin and muscle spasms associated with painful locomotor diseases. It is metabolized to the inactive metabolite mainly by CYP2D6 and, to a lesser extent, by CYP2C19 and CYP1A2. In our previous study, the pharmacokinetics of tolperisone was significantly affected by the genetic polymorphism of CYP2D6, but the wide interindividual variation of tolperisone pharmacokinetics was not explained by genetic polymorphism of CYP2D6 alone. Thus, we studied the effects of CYP2C19 genetic polymorphism on tolperisone pharmacokinetics. Eighty-one subjects with different CYP2C19 genotypes received a single oral dose of 150 mg tolperisone with 240 mL of water, and blood samples were collected up to 12 h after dosing. The plasma concentration of tolperisone was measured by a liquid chromatography-tandem mass spectrometry system. The CYP2C19PM group had significantly higher C and lower CL/F values than the CYP2C19EM and CYP2C19IM groups. The AUC of the CYP2C19PM group was 2.86-fold and 3.00-fold higher than the CYP2C19EM and CYP2C19IM groups, respectively. In conclusion, the genetic polymorphism of CYP2C19 significantly affected tolperisone pharmacokinetics. Tolperisone hydrochloride is a centrally-acting muscle relaxant used for relieving spasticities of neurological origin and muscle spasms associated with painful locomotor diseases. It is metabolized to the inactive metabolite mainly by CYP2D6 and, to a lesser extent, by CYP2C19 and CYP1A2. In our previous study, the pharmacokinetics of tolperisone was significantly affected by the genetic polymorphism of CYP2D6, but the wide interindividual variation of tolperisone pharmacokinetics was not explained by genetic polymorphism of CYP2D6 alone. Thus, we studied the effects of CYP2C19 genetic polymorphism on tolperisone pharmacokinetics. Eighty-one subjects with different CYP2C19 genotypes received a single oral dose of 150 mg tolperisone with 240 mL of water, and blood samples were collected up to 12 h after dosing. The plasma concentration of tolperisone was measured by a liquid chromatography-tandem mass spectrometry system. The CYP2C19PM group had significantly higher Cmax and lower CL/F values than the CYP2C19EM and CYP2C19IM groups. The AUCinf of the CYP2C19PM group was 2.86-fold and 3.00-fold higher than the CYP2C19EM and CYP2C19IM groups, respectively. In conclusion, the genetic polymorphism of CYP2C19 significantly affected tolperisone pharmacokinetics.Tolperisone hydrochloride is a centrally-acting muscle relaxant used for relieving spasticities of neurological origin and muscle spasms associated with painful locomotor diseases. It is metabolized to the inactive metabolite mainly by CYP2D6 and, to a lesser extent, by CYP2C19 and CYP1A2. In our previous study, the pharmacokinetics of tolperisone was significantly affected by the genetic polymorphism of CYP2D6, but the wide interindividual variation of tolperisone pharmacokinetics was not explained by genetic polymorphism of CYP2D6 alone. Thus, we studied the effects of CYP2C19 genetic polymorphism on tolperisone pharmacokinetics. Eighty-one subjects with different CYP2C19 genotypes received a single oral dose of 150 mg tolperisone with 240 mL of water, and blood samples were collected up to 12 h after dosing. The plasma concentration of tolperisone was measured by a liquid chromatography-tandem mass spectrometry system. The CYP2C19PM group had significantly higher Cmax and lower CL/F values than the CYP2C19EM and CYP2C19IM groups. The AUCinf of the CYP2C19PM group was 2.86-fold and 3.00-fold higher than the CYP2C19EM and CYP2C19IM groups, respectively. In conclusion, the genetic polymorphism of CYP2C19 significantly affected tolperisone pharmacokinetics. Tolperisone hydrochloride is a centrally-acting muscle relaxant used for relieving spasticities of neurological origin and muscle spasms associated with painful locomotor diseases. It is metabolized to the inactive metabolite mainly by CYP2D6 and, to a lesser extent, by CYP2C19 and CYP1A2. In our previous study, the pharmacokinetics of tolperisone was significantly affected by the genetic polymorphism of CYP2D6 , but the wide interindividual variation of tolperisone pharmacokinetics was not explained by genetic polymorphism of CYP2D6 alone. Thus, we studied the effects of CYP2C19 genetic polymorphism on tolperisone pharmacokinetics. Eighty-one subjects with different CYP2C19 genotypes received a single oral dose of 150 mg tolperisone with 240 mL of water, and blood samples were collected up to 12 h after dosing. The plasma concentration of tolperisone was measured by a liquid chromatography-tandem mass spectrometry system. The CYP2C19PM group had significantly higher C max and lower CL/F values than the CYP2C19EM and CYP2C19IM groups. The AUC inf of the CYP2C19PM group was 2.86-fold and 3.00-fold higher than the CYP2C19EM and CYP2C19IM groups, respectively. In conclusion, the genetic polymorphism of CYP2C19 significantly affected tolperisone pharmacokinetics. |
| Author | Byeon, Ji-Young Jang, Choon-Gon Lee, Yun Jeong Park, Hye-Jung Mu, Chou Yen Ko, Eunvin Kang, Pureum Cho, Chang‑Keun Lee, Seok-Yong |
| Author_xml | – sequence: 1 givenname: Chang‑Keun surname: Cho fullname: Cho, Chang‑Keun organization: School of Pharmacy, Sungkyunkwan University – sequence: 2 givenname: Ji-Young surname: Byeon fullname: Byeon, Ji-Young organization: School of Pharmacy, Sungkyunkwan University – sequence: 3 givenname: Pureum surname: Kang fullname: Kang, Pureum organization: School of Pharmacy, Sungkyunkwan University – sequence: 4 givenname: Hye-Jung surname: Park fullname: Park, Hye-Jung organization: School of Pharmacy, Sungkyunkwan University – sequence: 5 givenname: Eunvin surname: Ko fullname: Ko, Eunvin organization: School of Pharmacy, Sungkyunkwan University – sequence: 6 givenname: Chou Yen surname: Mu fullname: Mu, Chou Yen organization: School of Pharmacy, Sungkyunkwan University – sequence: 7 givenname: Choon-Gon surname: Jang fullname: Jang, Choon-Gon organization: School of Pharmacy, Sungkyunkwan University – sequence: 8 givenname: Seok-Yong orcidid: 0000-0003-4162-1981 surname: Lee fullname: Lee, Seok-Yong email: sylee@skku.ac.kr organization: School of Pharmacy, Sungkyunkwan University – sequence: 9 givenname: Yun Jeong surname: Lee fullname: Lee, Yun Jeong organization: College of Pharmacy, Dankook University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36564599$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002947099$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNqFkT9v1DAchi1URK-FL8CAPCKkFP-JHXusTgUqVQKhMjBZjuNcfJfYwXaG-_Z1L-3SoQzWuzzPq5_8XoAzH7wF4CNGVxih5mvChDSkQqQ8XBNaoTdgg2XDK9oIfgY2iDBaccLlObhIaY8Q5Yyxd-C8JK-ZlBvQ3vS9NTnB0MPt319kiyXcWW-zM3AO43EKcR5cmmDwMA8WzoOOkzbh4E7MycthnG10qVwHnYeD1WMejjAt7f6x-j142-sx2Q9PeQn-fLu53_6o7n5-v91e31WG1ixXlhvZ2lZiow0RVkiCGt0RSU3DMWamo4yYnghCOkmxaYU0shdtLUzdaY4MvQRf1l4fe3UwTgXtTrkL6hDV9e_7W4URwaRueIE_r_Acw7_Fpqwml4wdR-1tWJIiQhSKCin_jzZMYMxrKgr66Qld2sl2ao5u0vGonv-7AGIFTAwpRdsr47LOLvgctRvLfepxWrVOq8q06jStQkUlL9Tn9lclukqpwH5no9qHJfoyw2vWA33ItMw |
| CitedBy_id | crossref_primary_10_1016_j_rechem_2025_102098 crossref_primary_10_17116_pain20242204155 crossref_primary_10_1007_s12272_023_01476_9 crossref_primary_10_1007_s12272_023_01478_7 crossref_primary_10_1007_s12272_024_01495_0 crossref_primary_10_58502_DTT_23_0009 crossref_primary_10_1007_s12272_024_01531_z crossref_primary_10_1007_s12272_023_01448_z crossref_primary_10_12677_ACM_2023_1392090 crossref_primary_10_1007_s12272_023_01462_1 crossref_primary_10_1007_s12272_024_01528_8 crossref_primary_10_1007_s12272_023_01472_z |
| Cites_doi | 10.1007/s12272-022-01394-2 10.1007/s12272-020-01293-4 10.1016/S0021-9258(17)40694-6 10.1007/s12272-022-01403-4 10.1016/0731-7085(87)80082-1 10.1016/j.jchromb.2012.10.027 10.1002/jcph.323 10.1016/j.phrs.2019.104606 10.1124/jpet.105.089805 10.5414/cpp45110 10.1002/cpdd.966 10.1007/s12272-022-01422-1 10.1016/S1090-3801(02)00145-3 10.1007/s00228-018-2522-5 10.3109/15563650.2015.1022896 10.1007/s12272-021-01366-y 10.1124/dmd.31.5.631 10.1016/j.jphs.2019.03.001 10.1007/s12272-022-01388-0 10.1007/s12272-021-01346-2 10.1007/s12272-020-01294-3 10.1097/JCP.0b013e3182a608a2 10.1007/s12272-021-01361-3 10.1007/s00228-015-1856-5 10.1007/s12272-020-01250-1 10.1007/s12272-020-01300-8 10.1007/s12272-021-01357-z 10.1007/s12272-021-01363-1 10.1136/ejhpharm-2020-002367 10.1016/j.clpt.2005.10.002 10.1016/j.clinthera.2013.07.147 |
| ContentType | Journal Article |
| Copyright | The Pharmaceutical Society of Korea 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2022. The Pharmaceutical Society of Korea. |
| Copyright_xml | – notice: The Pharmaceutical Society of Korea 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2022. The Pharmaceutical Society of Korea. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 ACYCR |
| DOI | 10.1007/s12272-022-01423-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1976-3786 |
| EndPage | 116 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10212476 36564599 10_1007_s12272_022_01423_0 |
| Genre | Journal Article |
| GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .86 .UV .VR 06C 06D 0R~ 0VY 1N0 2.D 203 23N 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2WC 2~H 30V 3SX 4.4 406 408 40D 40E 53G 5GY 5VS 67N 67Z 6J9 6NX 8TC 8UJ 95- 95. 95~ 96X 9ZL AAAVM AABHQ AACDK AAHBH AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACREN ACSNA ACUDM ACZOJ ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFGCZ AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BGNMA C1A CAG COF CS3 CSCUP DDRTE DNIVK DPUIP EBLON EBS EIOEI EJD EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI H13 HF~ HG6 HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ IWAJR IXC IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV KPH KVFHK LLZTM M4Y MA- MZR N2Q N9A NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OVD P19 P2P PF0 PT4 PT5 QOK QOR QOS R89 R9I RHV RNI RNS ROL RPX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SCLPG SDE SDH SHX SISQX SJN SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 T16 TEORI TSG TSK TUC U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W48 WK6 WK8 YLTOR Z45 Z7U Z7V Z7W Z83 Z87 Z8O Z8P Z8Q Z91 ZMTXR ZOVNA ZZE ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION CGR CUY CVF ECM EIF NPM 7X8 ABRTQ 7S9 L.6 AABYN AAEOY AAFGU AAKSU AAYFA ABFGW ABKAS ACBMV ACBRV ACBYP ACIGE ACIPQ ACTTH ACVWB ACWMK ACYCR ADMDM ADOXG AEEQQ AEFTE AESTI AEVTX AFAFS AFNRJ AGGBP AGKHE AIMYW AJDOV AKQUC UNUBA Z7X |
| ID | FETCH-LOGICAL-c345t-e6c9beb91cac28e89207ad293c76115cd352cf2822d931cb89c9f8b48c4da60c3 |
| IEDL.DBID | U2A |
| ISSN | 0253-6269 1976-3786 |
| IngestDate | Wed Feb 28 03:40:42 EST 2024 Fri Jul 11 12:08:09 EDT 2025 Tue Aug 05 10:04:17 EDT 2025 Thu Apr 03 07:03:38 EDT 2025 Thu Apr 24 22:58:46 EDT 2025 Tue Jul 01 03:46:57 EDT 2025 Fri Feb 21 02:45:47 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Tolperisone Genotype CYP2C19 Pharmacokinetics Genetic polymorphism Pharmacogenomics |
| Language | English |
| License | 2022. The Pharmaceutical Society of Korea. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c345t-e6c9beb91cac28e89207ad293c76115cd352cf2822d931cb89c9f8b48c4da60c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 https://doi.org/10.1007/s12272-022-01423-0 |
| ORCID | 0000-0003-4162-1981 |
| PMID | 36564599 |
| PQID | 2758116438 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10212476 proquest_miscellaneous_2887633899 proquest_miscellaneous_2758116438 pubmed_primary_36564599 crossref_citationtrail_10_1007_s12272_022_01423_0 crossref_primary_10_1007_s12272_022_01423_0 springer_journals_10_1007_s12272_022_01423_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20230200 2023-02-00 2023-Feb 20230201 2023-02 |
| PublicationDateYYYYMMDD | 2023-02-01 |
| PublicationDate_xml | – month: 2 year: 2023 text: 20230200 |
| PublicationDecade | 2020 |
| PublicationPlace | Seoul |
| PublicationPlace_xml | – name: Seoul – name: Korea (South) |
| PublicationTitle | Archives of pharmacal research |
| PublicationTitleAbbrev | Arch. Pharm. Res |
| PublicationTitleAlternate | Arch Pharm Res |
| PublicationYear | 2023 |
| Publisher | Pharmaceutical Society of Korea 대한약학회 |
| Publisher_xml | – name: Pharmaceutical Society of Korea – name: 대한약학회 |
| References | Na, Jeon, Yoon, Choi, Yoon, Yu, Chung (CR27) 2021; 10 Kim, Kang, Cho, Jung, Park, Lee, Bae, Jang, Lee (CR20) 2021; 44 Kim, Cho, Kang, Park, Lee, Bae, Jang, Lee (CR21) 2022; 45 Kocsis, Farkas, Fodor, Bielik, Thán, Kolok, Gere, Csejtei, Tarnawa (CR22) 2005; 315 Choi, Bae, Lee, Lee, Jang, Lee (CR10) 2014; 34 Fukuda, Watanabe, Kudo, Oshima, Ito (CR14) 1970; 4 Miskolczi, Vereczkey, Frenkl (CR26) 1987; 5 Vora (CR32) 2010; 58 Lee, Kang, Cho, Park, Lee, Bae, Choi, Kim, Jang, Lee (CR24) 2022; 45 Lee, Byeon, Kim, Lee, Choi, Jang, Bae, Lee, Lee (CR23) 2018; 74 Sim, Risinger, Dahl, Aklillu, Christensen, Bertilsson, Ingelman-Sundberg (CR30) 2006; 79 Cho, Byeon, Kang, Park, Jang, Lee, Choi, Nae, Lee (CR8) 2023 Dalmadi, Leibinger, Szeberényi, Borbás, Farkas, Szombathelyi, Tihanyi (CR11) 2003; 31 Jung, Cho, Kang, Park, Lee, Bae, Choi, Jang, Lee (CR17) 2021; 44 Song, Li, Mao, Song, Liu, Zhang (CR31) 2022; 29 Kamiya, Inui, Hakamata, Miyakawa, Tanaka, Uchida, Namiki, Odagiri, Watanabe (CR18) 2019; 139 Bajaj, Arendt-Nielsen, Madeleine, Svensson (CR3) 2003; 7 Zhang, Zhang, Liu, Sun, Shen, Zhou, Zhang, Xie, Chen, Liu, Wang (CR34) 2020; 152 Jung, Lee, Byeon, Shin, Oh, Cho, Lim, Jang, Lee, Lee (CR15) 2020; 43 Karaźniewicz-Łada, Danielak, Rubiś, Burchardt, Oszkinis, Główka (CR19) 2014; 54 de Morais, Wilkinson, Blaisdell, Nakamura, Meyer, Goldstein (CR12) 1994; 269 Whang, Cho, Jung, Kang, Park, Lee, Choi, Bae, Kim, Jang, Lee (CR33) 2022; 45 Cho, Kang, Park, Lee, Bae, Jang, Lee (CR5) 2021; 44 Bae, Kim, Park, Myung, Jang, Lee (CR1) 2007; 45 Choi, Park, Lee, Lee, Jang, Bae, Lee (CR9) 2012; 911 Shin, Jung, Kang, Lim, Oh, Cho, Lee, Choi, Jang, Lee, Bae (CR29) 2020; 43 Jung, Lee, Kim, Kang, Lim, Cho, Jang, Lee, Bae (CR16) 2020; 43 Martos, Hofer, Rauber-Lüthy, Schenk-Jaeger, Kupferschmidt, Ceschi (CR25) 2015; 53 Bae, Oh, Yoon, Shin, Jung, Cho, Lim, Kang, Choi, Jang, Lee, Lee (CR2) 2020; 43 Byeon, Lee, Jeon, Lee, Kim, Bae, Jang, Lee (CR4) 2013; 35 Cho, Park, Kang, Moon, Lee, Bae, Jang, Lee (CR6) 2021; 44 Pawlowska, Bogiel, Duda, Sieradzki (CR28) 2015; 71 Cho, Kang, Park, Ko, Mu, Lee, Choi, Kim, Jang, Bae, Lee (CR7) 2022; 45 de Morais, Wilkinson, Blaisdell, Nakamura, Meyer, Goldstein (CR13) 1994; 46 CM Lee (1423_CR24) 2022; 45 CI Choi (1423_CR10) 2014; 34 SM de Morais (1423_CR13) 1994; 46 P Miskolczi (1423_CR26) 1987; 5 YH Kim (1423_CR20) 2021; 44 JY Na (1423_CR27) 2021; 10 EH Jung (1423_CR16) 2020; 43 M Karaźniewicz-Łada (1423_CR19) 2014; 54 JW Bae (1423_CR2) 2020; 43 CK Cho (1423_CR6) 2021; 44 C Song (1423_CR31) 2022; 29 CI Choi (1423_CR9) 2012; 911 P Kocsis (1423_CR22) 2005; 315 CK Cho (1423_CR7) 2022; 45 SS Whang (1423_CR33) 2022; 45 C Kamiya (1423_CR18) 2019; 139 B Dalmadi (1423_CR11) 2003; 31 CK Cho (1423_CR8) 2023 HJ Zhang (1423_CR34) 2020; 152 JY Byeon (1423_CR4) 2013; 35 EH Jung (1423_CR17) 2021; 44 HI Lee (1423_CR23) 2018; 74 A Vora (1423_CR32) 2010; 58 H Fukuda (1423_CR14) 1970; 4 V Martos (1423_CR25) 2015; 53 HB Shin (1423_CR29) 2020; 43 SM de Morais (1423_CR12) 1994; 269 EH Jung (1423_CR15) 2020; 43 SC Sim (1423_CR30) 2006; 79 JW Bae (1423_CR1) 2007; 45 CK Cho (1423_CR5) 2021; 44 NT Kim (1423_CR21) 2022; 45 M Pawlowska (1423_CR28) 2015; 71 P Bajaj (1423_CR3) 2003; 7 |
| References_xml | – volume: 45 start-page: 433 issue: 6 year: 2022 end-page: 445 ident: CR24 article-title: Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different genotypes publication-title: Arch Pharm Res doi: 10.1007/s12272-022-01394-2 – volume: 4 start-page: 125 year: 1970 end-page: 130 ident: CR14 article-title: Pharmacological studies on a centrally acting muscle relaxant, 2,4'-dimethyl-3-piperidinopropiophenone, Mydocalm publication-title: Pharmacometrics – volume: 43 start-page: 1207 issue: 11 year: 2020 end-page: 1213 ident: CR2 article-title: Effects of genetic polymorphism on the pharmacokinetics of metoclopramide publication-title: Arch Pharm Res doi: 10.1007/s12272-020-01293-4 – volume: 269 start-page: 15419 year: 1994 end-page: 15422 ident: CR12 article-title: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)40694-6 – volume: 58 start-page: 127 year: 2010 end-page: 128 ident: CR32 article-title: Tolperisone publication-title: J Assoc Physicians India – volume: 45 start-page: 584 issue: 8 year: 2022 end-page: 595 ident: CR33 article-title: Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different genotypes publication-title: Arch Pharm Res doi: 10.1007/s12272-022-01403-4 – volume: 5 start-page: 695 issue: 7 year: 1987 end-page: 700 ident: CR26 article-title: Gas-liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and comparative bioavailability studies publication-title: J Pharm Biomed Anal doi: 10.1016/0731-7085(87)80082-1 – volume: 911 start-page: 59 year: 2012 end-page: 63 ident: CR9 article-title: Determination of tolperisone in human plasma by liquid chromatography/tandem mass spectrometry for clinical application publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2012.10.027 – volume: 46 start-page: 594 year: 1994 end-page: 598 ident: CR13 article-title: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese publication-title: Mol Pharmacol – volume: 54 start-page: 874 issue: 8 year: 2014 end-page: 880 ident: CR19 article-title: The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases publication-title: J Clin Pharmacol doi: 10.1002/jcph.323 – volume: 152 start-page: 104606 year: 2020 ident: CR34 article-title: Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors publication-title: Pharmacol Res doi: 10.1016/j.phrs.2019.104606 – volume: 315 start-page: 1237 issue: 3 year: 2005 end-page: 1246 ident: CR22 article-title: Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.105.089805 – volume: 45 start-page: 110 issue: 2 year: 2007 end-page: 113 ident: CR1 article-title: Considerable interindividual variation in the pharmacokinetics of tolperisone HCl publication-title: Int J Clin Pharmacol Ther doi: 10.5414/cpp45110 – volume: 10 start-page: 1469 issue: 12 year: 2021 end-page: 1477 ident: CR27 article-title: Influence of CYP2C19 polymorphisms on the pharmacokinetics of omeprazole in elderly subjects publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.966 – year: 2023 ident: CR8 publication-title: Effects of allele on the pharmacokinetics of tolperisone doi: 10.1007/s12272-022-01422-1 – volume: 7 start-page: 407 year: 2003 end-page: 418 ident: CR3 article-title: Prophylactic tolperisone for post-exercise muscle soreness causes reduced isometric force: a double-blind radomized crossover control study publication-title: Eur J Pain doi: 10.1016/S1090-3801(02)00145-3 – volume: 74 start-page: 1417 issue: 11 year: 2018 end-page: 1426 ident: CR23 article-title: Effects of and genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-018-2522-5 – volume: 53 start-page: 470 issue: 5 year: 2015 end-page: 476 ident: CR25 article-title: Acute toxicity profile of tolperisone in overdose: observational poison centre-based study publication-title: Clin Toxicol (phila) doi: 10.3109/15563650.2015.1022896 – volume: 45 start-page: 114 issue: 2 year: 2022 end-page: 121 ident: CR21 article-title: Effects of and alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects publication-title: Arch Pharm Res doi: 10.1007/s12272-021-01366-y – volume: 31 start-page: 631 issue: 5 year: 2003 end-page: 636 ident: CR11 article-title: Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes publication-title: Drug Metab Dispos doi: 10.1124/dmd.31.5.631 – volume: 139 start-page: 361 issue: 4 year: 2019 end-page: 366 ident: CR18 article-title: Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype publication-title: J Pharmacol Sci doi: 10.1016/j.jphs.2019.03.001 – volume: 45 start-page: 352 issue: 5 year: 2022 end-page: 366 ident: CR7 article-title: Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to genetic polymorphism publication-title: Arch Pharm Res doi: 10.1007/s12272-022-01388-0 – volume: 44 start-page: 713 issue: 7 year: 2021 end-page: 724 ident: CR20 article-title: Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to genetic polymorphism publication-title: Arch Pharm Res doi: 10.1007/s12272-021-01346-2 – volume: 43 start-page: 1187 issue: 11 year: 2020 end-page: 1196 ident: CR29 article-title: ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan publication-title: Arch Pharm Res doi: 10.1007/s12272-020-01294-3 – volume: 34 start-page: 139 issue: 1 year: 2014 end-page: 142 ident: CR10 article-title: Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics publication-title: J Clin Psychopharmacol doi: 10.1097/JCP.0b013e3182a608a2 – volume: 44 start-page: 1076 issue: 12 year: 2021 end-page: 1090 ident: CR6 article-title: Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different genotypes publication-title: Arch Pharm Res doi: 10.1007/s12272-021-01361-3 – volume: 71 start-page: 699 issue: 6 year: 2015 end-page: 705 ident: CR28 article-title: Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-015-1856-5 – volume: 43 start-page: 976 issue: 9 year: 2020 end-page: 981 ident: CR15 article-title: Relationship between plasma exposure of zolpidem and genotype in healthy Korean subjects publication-title: Arch Pharm Res doi: 10.1007/s12272-020-01250-1 – volume: 43 start-page: 1356 issue: 12 year: 2020 end-page: 1363 ident: CR16 article-title: Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different genotypes publication-title: Arch Pharm Res doi: 10.1007/s12272-020-01300-8 – volume: 44 start-page: 1037 issue: 11 year: 2021 end-page: 1049 ident: CR5 article-title: Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to allele publication-title: Arch Pharm Res doi: 10.1007/s12272-021-01357-z – volume: 44 start-page: 1109 issue: 12 year: 2021 end-page: 1119 ident: CR17 article-title: Physiologically based pharmacokinetic modeling of candesartan related to genetic polymorphism in adult and pediatric patients publication-title: Arch Pharm Res doi: 10.1007/s12272-021-01363-1 – volume: 29 start-page: 198 issue: 4 year: 2022 end-page: 201 ident: CR31 article-title: Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy publication-title: Eur J Hosp Pharm doi: 10.1136/ejhpharm-2020-002367 – volume: 79 start-page: 103 issue: 1 year: 2006 end-page: 113 ident: CR30 article-title: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.10.002 – volume: 35 start-page: e54 issue: 8 year: 2013 ident: CR4 article-title: Pharmacokinetics of tolperisone in relation to CYP2C19 genotypes publication-title: Clinical Therapeutics doi: 10.1016/j.clinthera.2013.07.147 – volume: 4 start-page: 125 year: 1970 ident: 1423_CR14 publication-title: Pharmacometrics – volume: 54 start-page: 874 issue: 8 year: 2014 ident: 1423_CR19 publication-title: J Clin Pharmacol doi: 10.1002/jcph.323 – volume: 10 start-page: 1469 issue: 12 year: 2021 ident: 1423_CR27 publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.966 – volume: 7 start-page: 407 year: 2003 ident: 1423_CR3 publication-title: Eur J Pain doi: 10.1016/S1090-3801(02)00145-3 – volume: 45 start-page: 114 issue: 2 year: 2022 ident: 1423_CR21 publication-title: Arch Pharm Res doi: 10.1007/s12272-021-01366-y – volume: 269 start-page: 15419 year: 1994 ident: 1423_CR12 publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)40694-6 – volume: 152 start-page: 104606 year: 2020 ident: 1423_CR34 publication-title: Pharmacol Res doi: 10.1016/j.phrs.2019.104606 – volume: 43 start-page: 1187 issue: 11 year: 2020 ident: 1423_CR29 publication-title: Arch Pharm Res doi: 10.1007/s12272-020-01294-3 – volume: 44 start-page: 713 issue: 7 year: 2021 ident: 1423_CR20 publication-title: Arch Pharm Res doi: 10.1007/s12272-021-01346-2 – volume: 44 start-page: 1037 issue: 11 year: 2021 ident: 1423_CR5 publication-title: Arch Pharm Res doi: 10.1007/s12272-021-01357-z – volume: 58 start-page: 127 year: 2010 ident: 1423_CR32 publication-title: J Assoc Physicians India – volume: 43 start-page: 1207 issue: 11 year: 2020 ident: 1423_CR2 publication-title: Arch Pharm Res doi: 10.1007/s12272-020-01293-4 – volume: 43 start-page: 1356 issue: 12 year: 2020 ident: 1423_CR16 publication-title: Arch Pharm Res doi: 10.1007/s12272-020-01300-8 – volume: 315 start-page: 1237 issue: 3 year: 2005 ident: 1423_CR22 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.105.089805 – volume: 34 start-page: 139 issue: 1 year: 2014 ident: 1423_CR10 publication-title: J Clin Psychopharmacol doi: 10.1097/JCP.0b013e3182a608a2 – volume: 31 start-page: 631 issue: 5 year: 2003 ident: 1423_CR11 publication-title: Drug Metab Dispos doi: 10.1124/dmd.31.5.631 – volume: 5 start-page: 695 issue: 7 year: 1987 ident: 1423_CR26 publication-title: J Pharm Biomed Anal doi: 10.1016/0731-7085(87)80082-1 – volume: 71 start-page: 699 issue: 6 year: 2015 ident: 1423_CR28 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-015-1856-5 – volume: 45 start-page: 110 issue: 2 year: 2007 ident: 1423_CR1 publication-title: Int J Clin Pharmacol Ther doi: 10.5414/cpp45110 – volume: 46 start-page: 594 year: 1994 ident: 1423_CR13 publication-title: Mol Pharmacol – volume: 45 start-page: 352 issue: 5 year: 2022 ident: 1423_CR7 publication-title: Arch Pharm Res doi: 10.1007/s12272-022-01388-0 – volume-title: Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone year: 2023 ident: 1423_CR8 doi: 10.1007/s12272-022-01422-1 – volume: 43 start-page: 976 issue: 9 year: 2020 ident: 1423_CR15 publication-title: Arch Pharm Res doi: 10.1007/s12272-020-01250-1 – volume: 44 start-page: 1109 issue: 12 year: 2021 ident: 1423_CR17 publication-title: Arch Pharm Res doi: 10.1007/s12272-021-01363-1 – volume: 44 start-page: 1076 issue: 12 year: 2021 ident: 1423_CR6 publication-title: Arch Pharm Res doi: 10.1007/s12272-021-01361-3 – volume: 45 start-page: 584 issue: 8 year: 2022 ident: 1423_CR33 publication-title: Arch Pharm Res doi: 10.1007/s12272-022-01403-4 – volume: 139 start-page: 361 issue: 4 year: 2019 ident: 1423_CR18 publication-title: J Pharmacol Sci doi: 10.1016/j.jphs.2019.03.001 – volume: 79 start-page: 103 issue: 1 year: 2006 ident: 1423_CR30 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.10.002 – volume: 911 start-page: 59 year: 2012 ident: 1423_CR9 publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2012.10.027 – volume: 29 start-page: 198 issue: 4 year: 2022 ident: 1423_CR31 publication-title: Eur J Hosp Pharm doi: 10.1136/ejhpharm-2020-002367 – volume: 35 start-page: e54 issue: 8 year: 2013 ident: 1423_CR4 publication-title: Clinical Therapeutics doi: 10.1016/j.clinthera.2013.07.147 – volume: 74 start-page: 1417 issue: 11 year: 2018 ident: 1423_CR23 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-018-2522-5 – volume: 45 start-page: 433 issue: 6 year: 2022 ident: 1423_CR24 publication-title: Arch Pharm Res doi: 10.1007/s12272-022-01394-2 – volume: 53 start-page: 470 issue: 5 year: 2015 ident: 1423_CR25 publication-title: Clin Toxicol (phila) doi: 10.3109/15563650.2015.1022896 |
| SSID | ssj0036555 |
| Score | 2.3925965 |
| Snippet | Tolperisone hydrochloride is a centrally-acting muscle relaxant used for relieving spasticities of neurological origin and muscle spasms associated with... |
| SourceID | nrf proquest pubmed crossref springer |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 111 |
| SubjectTerms | blood Cytochrome P-450 CYP2C19 - genetics Cytochrome P-450 CYP2D6 - genetics genetic polymorphism Genotype Healthy Volunteers Humans liquid chromatography Medicine metabolites muscle relaxants muscles oral administration pharmacokinetics Pharmacology/Toxicology Pharmacy Polymorphism, Genetic Research Article tandem mass spectrometry Tolperisone - pharmacokinetics 약학 |
| Title | Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects |
| URI | https://link.springer.com/article/10.1007/s12272-022-01423-0 https://www.ncbi.nlm.nih.gov/pubmed/36564599 https://www.proquest.com/docview/2758116438 https://www.proquest.com/docview/2887633899 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002947099 |
| Volume | 46 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Archives of Pharmacal Research, 2023, 46(2), , pp.111-116 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fT9swELYGSBMviLHByhgy2sTLaqmxHSd-LBUdA4H6QCV4smI7maqWpGrah_73u8sPqmmo0p78EDuxfGf7u9zdd4R8t4FNEmVTlmBoowxFyKxWjlnQDutkJp2vAmQf1M1Y3j6FT01SWNlGu7cuyeqk3iS7cR5xhtHnAOu5YGCo74Vgu2Mg15j32_NXqLCqdQqXuWAA13WTKvP2O_66jnbyRfYW0vzHS1pdPsNDctCgRtqvxfyBvEvzI_L-vvGLH5HLUc1Ave7Sx01CVdmll3S04aZefyS2ZisuaZHRwfOIDwJNQYUwk5HOi9n6pYB1n5QvtMgpQEM6b0ZPJ1WfatyymCE9MgD1lE5yWmdSrmm5svhPp_xExsPrx8ENa8osMCdkuGSpctqmVgcucTxOY817UeIBBrhIAV50HjCayzDc1GsROBtrp7PYythJn6ieE8dkN4dPfiZUeJllmJsrJCAD7a2LfGB94i2cq5GKOiRoV9u4hoMcS2HMzIY9GSVkQEKmkpDpdciP1zHzmoFja-9vIEQzdRODxNnY_i7MdGHAPPhlsI45l5HqkItWyAa2E_pIkjwtVqXhYD8FYEKKeEufGGn8kJiwQ05qDXmdGWgf0vPAk26rMqY5Fcot0z79v-5fyD6Wva-jx8_I7nKxSr8COFrac7LXH15dPWD78_nu-rzaG38AfoMGjA |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swEBdrC-teRr_WZp8aG31ZBLEky9ZjCSvp1pY8JNA-CUuyS0hqhzh5yH-_O380lJbAnvRgyRa60-kn393vCPlpA5skyqYswdBGGYqQWa0cs6Ad1slMOl8FyN6qwVj-uQvvmqSwso12b12SlaXeJLtxHnGG0ecA67lgcFHfgzZGXR7zi9b-ChVWtU7hMBcM4LpuUmVef8ez42gnX2SvIc0XXtLq8Lk8IO8b1EgvajEfkjdpfkTe3jR-8SNyPqwZqNddOtokVJVdek6HG27q9TGxNVtxSYuM9u-HvB9oCiqEmYx0XszWjwWs-6R8pEVOARrSeTN6Oqn6VOOWxQzpkQGop3SS0zqTck3LlcV_OuUJGV_-HvUHrCmzwJyQ4ZKlymmbWh24xPE4jTXvRYkHGOAiBXjRecBoLsNwU69F4Gysnc5iK2MnfaJ6Tnwguzl88oxQ4WWWYW6ukIAMtLcu8oH1ibdgVyMVdUjQrrZxDQc5lsKYmQ17MkrIgIRMJSHT65BfT2PmNQPH1t4_QIhm6iYGibOxfSjMdGHgenBlsI45l5HqkO-tkA1sJ_SRJHlarErD4f4UwBVSxFv6xEjjh8SEHXJaa8jTzED7kJ4HnnRblTGNVSi3TPvj_3X_RvYHo5trc311-_cTecd7qMqo05_J7nKxSr8AUFrar9W--AeUtAZv |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NT9swFLcYSGiXaYN9dF942sRltWhsx4mPqKMCxlAPVGInK7YTVLUkVZMe-t_vvXzQTUOVOOWQ58TKe7Z_L36_nwn5ZgObJMqmLMHSRhmKkFmtHLMQHdbJTDpfF8heq_OJvLwNb_9i8dfV7t2WZMNpQJWmvDpZ-OxkQ3zjPOIMK9EB4nPBIGnfk8gGhoie8NNuLhYqrM89hYVdMIDuuqXNPP6Mf5amZ_kyewx1_rdjWi9Eo5fkRYsg6Wnj8ldkJ80PyP6vdo_8gByPGzXqdZ_ebMhVZZ8e0_FGp3p9SGyjXFzSIqPD32M-DDSFcEJWI10U8_V9AT6Ylve0yCnARLpoW8-mtU3drirmKJUMoD2l05w2rMo1LVcW_--Ur8lkdHYzPGftkQvMCRlWLFVO29TqwCWOx2ms-SBKPEACFynAjs4DXnMZlp56LQJnY-10FlsZO-kTNXDiDdnN4ZXvCBVeZhnydIUElKC9dZEPrE-8hTk2UlGPBN3XNq7VI8djMeZmo6SMHjLgIVN7yAx65PtDm0WjxrHV-is40czc1KCINl7vCjNbGkgVLgyeac5lpHrkS-dkA0ML90uSPC1WpeGQSwWQTop4i02Mkn4oUtgjb5sIeegZRB9K9cCdfhcypp0hyi3dfv808yOyP_4xMlcX1z8_kOd8gJGMIf2R7FbLVfoJMFNlP9fD4g-MXQqi |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+CYP2C19+genetic+polymorphism+on+the+pharmacokinetics+of+tolperisone+in+healthy+subjects&rft.jtitle=Archives+of+pharmacal+research&rft.au=Cho%2C+Chang%E2%80%91Keun&rft.au=Byeon%2C+Ji-Young&rft.au=Kang%2C+Pureum&rft.au=Park%2C+Hye-Jung&rft.date=2023-02-01&rft.pub=Pharmaceutical+Society+of+Korea&rft.issn=0253-6269&rft.eissn=1976-3786&rft.volume=46&rft.issue=2&rft.spage=111&rft.epage=116&rft_id=info:doi/10.1007%2Fs12272-022-01423-0&rft.externalDocID=10_1007_s12272_022_01423_0 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0253-6269&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0253-6269&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0253-6269&client=summon |